J&J heats up RSV race with new vaccine data

Johnson & Johnson's experimental vaccine for respiratory syncytial virus, or RSV, prevented complications in people 65 and older, with the company reporting Saturday treatment reduced cases of lower respiratory tract disease by 80% in a mid-stage trial.